» Articles » PMID: 37554301

Mitochondrial DNA-targeted Therapy: A Novel Approach to Combat Cancer

Overview
Journal Cell Insight
Date 2023 Aug 9
PMID 37554301
Authors
Affiliations
Soon will be listed here.
Abstract

Mitochondrial DNA (mtDNA) encodes proteins and RNAs that are essential for mitochondrial function and cellular homeostasis, and participates in important processes of cellular bioenergetics and metabolism. Alterations in mtDNA are associated with various diseases, especially cancers, and are considered as biomarkers for some types of tumors. Moreover, mtDNA alterations have been found to affect the proliferation, progression and metastasis of cancer cells, as well as their interactions with the immune system and the tumor microenvironment (TME). The important role of mtDNA in cancer development makes it a significant target for cancer treatment. In recent years, many novel therapeutic methods targeting mtDNA have emerged. In this study, we first discussed how cancerogenesis is triggered by mtDNA mutations, including alterations in gene copy number, aberrant gene expression and epigenetic modifications. Then, we described in detail the mechanisms underlying the interactions between mtDNA and the extramitochondrial environment, which are crucial for understanding the efficacy and safety of mtDNA-targeted therapy. Next, we provided a comprehensive overview of the recent progress in cancer therapy strategies that target mtDNA. We classified them into two categories based on their mechanisms of action: indirect and direct targeting strategies. Indirect targeting strategies aimed to induce mtDNA damage and dysfunction by modulating pathways that are involved in mtDNA stability and integrity, while direct targeting strategies utilized molecules that can selectively bind to or cleave mtDNA to achieve the therapeutic efficacy. This study highlights the importance of mtDNA-targeted therapy in cancer treatment, and will provide insights for future research and development of targeted drugs and therapeutic strategies.

Citing Articles

Modification in Structures of Active Compounds in Anticancer Mitochondria-Targeted Therapy.

Pyrczak-Felczykowska A, Herman-Antosiewicz A Int J Mol Sci. 2025; 26(3).

PMID: 39941144 PMC: 11818413. DOI: 10.3390/ijms26031376.


Mitochondrial DNA copy number alterations: Key players in the complexity of glioblastoma (Review).

Yusoff A, Mohd Khair S, Abd Radzak S Mol Med Rep. 2025; 31(3).

PMID: 39886971 PMC: 11795256. DOI: 10.3892/mmr.2025.13443.


Mitochondrial DNA variants in the pathogenesis and metabolic alterations of diabetes mellitus.

K S P, Jyothi M, Prashant A Mol Genet Metab Rep. 2025; 42():101183.

PMID: 39835172 PMC: 11743804. DOI: 10.1016/j.ymgmr.2024.101183.


Combining Photodynamic Therapy and Targeted Drug Delivery Systems: Enhancing Mitochondrial Toxicity for Improved Cancer Outcomes.

Merlin J, Crous A, Abrahamse H Int J Mol Sci. 2024; 25(19).

PMID: 39409125 PMC: 11477455. DOI: 10.3390/ijms251910796.


Research progress on mitochondria regulating tumor immunity.

Li J, Xu P, Chen S Zhejiang Da Xue Xue Bao Yi Xue Ban. 2024; 53(1):1-14.

PMID: 38229501 PMC: 10945498. DOI: 10.3724/zdxbyxb-2023-0484.

References
1.
Hillen H, Morozov Y, Sarfallah A, Temiakov D, Cramer P . Structural Basis of Mitochondrial Transcription Initiation. Cell. 2017; 171(5):1072-1081.e10. PMC: 6590061. DOI: 10.1016/j.cell.2017.10.036. View

2.
Berridge M, Dong L, Neuzil J . Mitochondrial DNA in Tumor Initiation, Progression, and Metastasis: Role of Horizontal mtDNA Transfer. Cancer Res. 2015; 75(16):3203-8. DOI: 10.1158/0008-5472.CAN-15-0859. View

3.
Huertas J, Al Fazazi S, Hidalgo-Gutierrez A, Lopez L, Casuso R . Antioxidant effect of exercise: Exploring the role of the mitochondrial complex I superassembly. Redox Biol. 2017; 13:477-481. PMC: 5512182. DOI: 10.1016/j.redox.2017.07.009. View

4.
Valdez-Alegria C, Fuentes-Rivas R, Garcia-Rivas J, Zavala Arce R, Jimenez Nunez M, Garcia-Gaitan B . Synthesis of Chitosan-Polyvinyl Alcohol Biopolymers to Eliminate Fluorides from Water. Biomolecules. 2020; 10(1). PMC: 7023337. DOI: 10.3390/biom10010156. View

5.
Arevalo J, Amorim J . Virtual screening, optimization and molecular dynamics analyses highlighting a pyrrolo[1,2-a]quinazoline derivative as a potential inhibitor of DNA gyrase B of Mycobacterium tuberculosis. Sci Rep. 2022; 12(1):4742. PMC: 8933452. DOI: 10.1038/s41598-022-08359-x. View